TD Cowen Downgrades Pfizer to Market Perform, Announces $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Steve Scala has downgraded Pfizer (NYSE:PFE) from Outperform to Market Perform and set a price target of $32.

January 04, 2024 | 11:00 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pfizer downgraded by TD Cowen from Outperform to Market Perform with a new price target of $32.
Downgrades by analysts can lead to a negative perception among investors, potentially causing a short-term decline in the stock price. The new price target of $32 suggests a lower expected future price, which could further contribute to downward pressure on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100